sHLH is induced in mice through the administration of CpG-1826 and anti-IL-10R antibodies. Treatment with PRT382, a selective PRMT5 inhibitor, mitigates HLH-associated pathology, including splenomegaly, hepatomegaly, and anemia, while normalizing IFN-γ and IL-6 levels.